<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; global</title>
	<atom:link href="http://www.tapanray.in/tag/global/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>From Share-of-Voice to Share-of-Outcomes: How Indian Pharma Is Rewriting Marketing</title>
		<link>http://www.tapanray.in/from-share-of-voice-to-share-of-outcomes-how-indian-pharma-is-rewriting-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=from-share-of-voice-to-share-of-outcomes-how-indian-pharma-is-rewriting-marketing</link>
		<comments>http://www.tapanray.in/from-share-of-voice-to-share-of-outcomes-how-indian-pharma-is-rewriting-marketing/#comments</comments>
		<pubDate>Sun, 07 Sep 2025 07:39:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rewriting]]></category>
		<category><![CDATA[share of outcomes]]></category>
		<category><![CDATA[share of voice]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10967</guid>
		<description><![CDATA[If you zoom out on India’s pharma market over the past 18 months, one pattern jumps off the page: marketing is no longer just about pushing brands; it’s about owning moments across the care journey - from the first symptom search to &#8230; <a href="http://www.tapanray.in/from-share-of-voice-to-share-of-outcomes-how-indian-pharma-is-rewriting-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/from-share-of-voice-to-share-of-outcomes-how-indian-pharma-is-rewriting-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Indian Pharma Marketing’s AI Moment: Lead the Change or Fall Behind</title>
		<link>http://www.tapanray.in/indian-pharma-marketings-ai-moment-lead-the-change-or-fall-behind/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-pharma-marketings-ai-moment-lead-the-change-or-fall-behind</link>
		<comments>http://www.tapanray.in/indian-pharma-marketings-ai-moment-lead-the-change-or-fall-behind/#comments</comments>
		<pubDate>Fri, 23 May 2025 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[adoption]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[behind]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Checklist]]></category>
		<category><![CDATA[fall]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[identities]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[Lead]]></category>
		<category><![CDATA[leaders]]></category>
		<category><![CDATA[lifeline]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[moment]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[ROI]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10899</guid>
		<description><![CDATA[(With An Actionable AI Adoption Checklist below for Indian Pharma Marketers) India’s pharmaceutical market is one of the most complex and exciting in the world. With over 60,000 brands battling for attention, millions of patients, and a healthcare landscape rapidly evolving, &#8230; <a href="http://www.tapanray.in/indian-pharma-marketings-ai-moment-lead-the-change-or-fall-behind/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-pharma-marketings-ai-moment-lead-the-change-or-fall-behind/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Regulatory Failures Are Still Risking Patient Lives</title>
		<link>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=regulatory-failures-are-still-risking-patient-lives</link>
		<comments>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/#comments</comments>
		<pubDate>Sun, 06 Oct 2024 06:37:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[failures]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[lives]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[risking]]></category>
		<category><![CDATA[self-regulation]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[substandard]]></category>
		<category><![CDATA[sustainabilitycompanies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TechnologyAwareness]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10880</guid>
		<description><![CDATA[India&#8217;s pharmaceutical industry faces renewed scrutiny as the Drug Controller General of India (DCGI) flagged numerous substandard drugs in September 2024. At the same time, an October 02, 2024, Business Standard report highlights an ongoing crackdown on such drugs by regulators. This article explores &#8230; <a href="http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Transformational Approach To Patient-Driven Pharma Marketing</title>
		<link>http://www.tapanray.in/a-transformational-approach-to-patient-driven-pharma-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-transformational-approach-to-patient-driven-pharma-marketing</link>
		<comments>http://www.tapanray.in/a-transformational-approach-to-patient-driven-pharma-marketing/#comments</comments>
		<pubDate>Fri, 23 Feb 2024 07:58:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RWE]]></category>
		<category><![CDATA[Synthesis]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transformational]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10855</guid>
		<description><![CDATA[This new-era approach to gain a cutting-edge in drug marketing is fast gathering winds on its sail &#8211; the world over and is being accepted as a transformational one, in tandem. It is primarily a two-pronged approach that involves merging or convergence &#8230; <a href="http://www.tapanray.in/a-transformational-approach-to-patient-driven-pharma-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-transformational-approach-to-patient-driven-pharma-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Unleash The Power of RWE in Indian Pharma Marketing</title>
		<link>http://www.tapanray.in/unleash-the-power-of-rwe-in-indian-pharma-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unleash-the-power-of-rwe-in-indian-pharma-marketing</link>
		<comments>http://www.tapanray.in/unleash-the-power-of-rwe-in-indian-pharma-marketing/#comments</comments>
		<pubDate>Sat, 10 Feb 2024 06:59:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Phaemaceutical]]></category>
		<category><![CDATA[power]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Real World Evidence]]></category>
		<category><![CDATA[RWE]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Unleash]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10851</guid>
		<description><![CDATA[An IQIVIA event titled, “RWE in 2024: Recognizing opportunity and demonstrating value with confidence,” held on October 25-26, 2023, made several interesting observations such as: The future of healthcare is being reshaped and RWE is playing an increasing role in revolutionizing patient &#8230; <a href="http://www.tapanray.in/unleash-the-power-of-rwe-in-indian-pharma-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unleash-the-power-of-rwe-in-indian-pharma-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Pharma Growth Strategy Now Extends Beyond Human Intelligence</title>
		<link>http://www.tapanray.in/how-pharma-growth-strategy-now-extends-beyond-human-intelligence/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-pharma-growth-strategy-now-extends-beyond-human-intelligence</link>
		<comments>http://www.tapanray.in/how-pharma-growth-strategy-now-extends-beyond-human-intelligence/#comments</comments>
		<pubDate>Fri, 08 Dec 2023 06:00:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[examples]]></category>
		<category><![CDATA[generative]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Microsoft]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10844</guid>
		<description><![CDATA[That the drug Industry’s growth strategy now extends beyond human intelligence, across the value chain, are being vindicated by several reports, around the world since several years. Illustratively, on September 1, 2019, Novartis and Microsoft announced a multiyear alliance which will leverage data &#8230; <a href="http://www.tapanray.in/how-pharma-growth-strategy-now-extends-beyond-human-intelligence/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-pharma-growth-strategy-now-extends-beyond-human-intelligence/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>With Covid’s Second Wave ‘A Nation In Distress’ &#8211; Why?</title>
		<link>http://www.tapanray.in/with-covids-second-wave-a-nation-in-distress-why/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-covids-second-wave-a-nation-in-distress-why</link>
		<comments>http://www.tapanray.in/with-covids-second-wave-a-nation-in-distress-why/#comments</comments>
		<pubDate>Mon, 19 Apr 2021 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[A Nation in distress]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[clinically]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Covishield]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[First]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[proven]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Second]]></category>
		<category><![CDATA[shortage]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Vaccine]]></category>
		<category><![CDATA[wave]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10475</guid>
		<description><![CDATA[If someone tries to see a silver lining in the disruptive Covid-19 pandemic, besides its vaccine rollout in some countries, there will be at least one. As of April 17, 2021- over 119 million patients (India &#8211; over 12 million), reportedly, &#8230; <a href="http://www.tapanray.in/with-covids-second-wave-a-nation-in-distress-why/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-covids-second-wave-a-nation-in-distress-why/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Shifting Pharma Supply Chain Strategy From Global To Local</title>
		<link>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=shifting-pharma-supply-chain-strategy-from-global-to-local</link>
		<comments>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/#comments</comments>
		<pubDate>Mon, 08 Jun 2020 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[lobbyists]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Procurement]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reevaluating]]></category>
		<category><![CDATA[shifting]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vulnerability]]></category>
		<category><![CDATA[Vulnerable]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10120</guid>
		<description><![CDATA[Alongside large-scale disruptions of many critical industrial operations, Covid-19 global pandemic took the wind out of the sail of pharma supply chain, as well, at the very onset of lockdowns. This happened in many countries around the world, including the &#8230; <a href="http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma ‘Chatbots’: For Better Stakeholder Engagement</title>
		<link>http://www.tapanray.in/pharma-chatbots-for-better-stakeholder-engagement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-chatbots-for-better-stakeholder-engagement</link>
		<comments>http://www.tapanray.in/pharma-chatbots-for-better-stakeholder-engagement/#comments</comments>
		<pubDate>Mon, 29 Jul 2019 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[answers]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[assistant]]></category>
		<category><![CDATA[automated]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[Chatbots]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[functions]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Merck & Co]]></category>
		<category><![CDATA[Novo Nordisk]]></category>
		<category><![CDATA[outlook]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[Privacy]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[questions]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[satisfaction]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[virtual]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9647</guid>
		<description><![CDATA[The critical value of meaningful interaction and engagement with individual customers &#8211; responding to their specific needs, is fast drawing attention of many businesses, for sustainable performance excellence. The same is happening in the pharma industry, as well. Creative use &#8230; <a href="http://www.tapanray.in/pharma-chatbots-for-better-stakeholder-engagement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-chatbots-for-better-stakeholder-engagement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Diversity And Inclusion’: A Missing Link For Indian Pharma</title>
		<link>http://www.tapanray.in/diversity-and-inclusion-a-missing-link-for-indian-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=diversity-and-inclusion-a-missing-link-for-indian-pharma</link>
		<comments>http://www.tapanray.in/diversity-and-inclusion-a-missing-link-for-indian-pharma/#comments</comments>
		<pubDate>Mon, 25 Jun 2018 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[culture]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[DI]]></category>
		<category><![CDATA[Diversity]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[inclusion]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[link]]></category>
		<category><![CDATA[Missing]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[oriented]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9015</guid>
		<description><![CDATA[Inadequate access to affordable health care to a vast majority of the population has been a favorite topic of debate, since long, globally. This discourse is generally centered around the least developed and the developing world, such as India. However, &#8230; <a href="http://www.tapanray.in/diversity-and-inclusion-a-missing-link-for-indian-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/diversity-and-inclusion-a-missing-link-for-indian-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
